Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]
Awaiting development
Reference number: GID-TA10657
Expected publication date: TBC
Following the written consultation on the draft scope and discussions at the scoping workshop, NICE compiled a summary of its findings into a report that was discussed at the Topic Selection Oversight Panel in October 2020. The report included advice and recommendations to aid the decision-making process as to whether the topic should continue to be evaluated in the NICE work programme.
The Topic Selection Oversight Panel concluded that an appraisal of ibalizumab in combination with other antiretroviral treatment for multidrug-resistant HIV-1 would be of limited value to the NHS at this time and therefore the topic will not progress any further